NEW YORK – Illumina and PierianDx announced Tuesday an expanded partnership for next-generation sequencing-based cancer panel reporting.
Under the terms of the agreement, PierianDx's genomic reporting products, including the Clinical Genomics Workspace and Clinical Genomics Knowledgebase, will be enabled for use with the AmpliSeq for Illumina Focus panel, AmpliSeq for Illumina Myeloid panel, and the Illumina TruSight Hereditary Cancer Panel.
Financial and other terms of the deal were not disclosed.
Previously, the PierianDx platform provided variant interpretation and reporting for the TruSight Oncology 500 portfolio, following a non-exclusive multi-year deal announced in January 2019.
"PierianDx has demonstrated its commitment to best-in-class variant reporting solutions," Illumina CMO Phil Febbo said in a statement. "We are excited to expand our partnership to cover the AmpliSeqsuite of panels which are optimized for clinical cancer research."
In October, Creve Coeur, Missouri-based PierianDx signed a deal to integrate its genomic reports with Pillar Biosciences' NGS cancer profiling assays and to comarket the product.